Xencor Inc (XNCR) VP John J. Kuch Sells 15,000 Shares of Stock
Xencor Inc (NASDAQ:XNCR) VP John J. Kuch sold 15,000 shares of the business’s stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $24.42, for a total transaction of $366,300.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Xencor Inc (NASDAQ:XNCR) traded up 0.75% on Monday, hitting $24.29. 172,007 shares of the stock traded hands. The firm has a market capitalization of $1.13 billion, a PE ratio of 43.38 and a beta of 2.21. The stock has a 50 day moving average of $24.20 and a 200 day moving average of $23.95. Xencor Inc has a 52 week low of $10.95 and a 52 week high of $29.38.
Your IP Address:
Several large investors have recently bought and sold shares of the company. DIAM Co. Ltd. purchased a new stake in Xencor during the third quarter valued at $154,000. Oberweis Asset Management Inc. purchased a new stake in Xencor during the fourth quarter valued at $211,000. Zacks Investment Management purchased a new stake in Xencor during the third quarter valued at $249,000. Matarin Capital Management LLC purchased a new stake in Xencor during the third quarter valued at $329,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Xencor during the fourth quarter valued at $370,000. Institutional investors own 64.14% of the company’s stock.
XNCR has been the topic of several analyst reports. TheStreet raised shares of Xencor from a “sell” rating to a “hold” rating in a research report on Friday, December 2nd. Zacks Investment Research cut shares of Xencor from a “hold” rating to a “sell” rating in a research report on Wednesday, January 11th. Nomura initiated coverage on shares of Xencor in a research report on Wednesday, March 1st. They set a “neutral” rating on the stock. Canaccord Genuity set a $32.00 price target on shares of Xencor and gave the stock a “buy” rating in a research report on Monday, November 28th. Finally, Instinet initiated coverage on shares of Xencor in a research report on Wednesday, March 1st. They set a “neutral” rating and a $21.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Xencor has a consensus rating of “Buy” and a consensus target price of $29.33.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.
Receive News & Ratings for Xencor Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.